Scworx Corp

Scworx Corp(WORX)股票分析

$2.680

+2.525 (+94.20%)收盘时

Loading chart…
最高
3.770
开盘
1.390
成交量加权均价
2.60
成交量
126.02M
市值
2.08M
最低
1.350
成交额
327.65M
企业价值/息税折旧摊销前利润(TTM)
0.00

SCWorx Corp. is a provider of data content and services related to the repair, normalization and interoperability of information for healthcare providers, as well as big data analytics for the healthcare industry. The Company has developed and markets health care information technology solutions and associated services that enhance healthcare processes and information flow within hospitals and other healthcare facilities. Its software enables a healthcare provider to simplify and organize its data (data normalization), allows the data to be utilized across multiple internal software applications and provides the basis for sophisticated data analytics (big data). Its software modules include virtualized item master file repair, expansion and automation, electronic medical record management, charge description master management, contract management, request for proposal (RFP) automation, integration of acquired businesses, rebate management, and data integration and warehousing.

AI 分析 of Scworx Corp (WORX)

卖出

Worx Corp is not a good buy right now due to significant declines in stock performance and negative financial indicators. The current price is $1.38, which is down 96.22% year-to-date, indicating severe underperformance. Additionally, the RSI is at an extremely low level of 5.451, suggesting that the stock is oversold, but this could also indicate a lack of buying interest. The forward P/E ratio is 0, reflecting no expected earnings growth, and the gross margin, while improving to 46.67% in Q2 2026, is overshadowed by a net margin of -17.13%. The main risk is the substantial 94.04% decline over the past 20 days, indicating a strong downward trend.

估值指标

Scworx Corp(WORX)当前预期市盈率为 0.00,5 年平均预期市盈率为 0.00。

预期市盈率

严重低估
5 年均值 P/E
0.00
当前P/E
0.00
高估
0.00
低估
0.00

预期 EV/EBITDA

严重低估
5 年均值 EV/EBITDA
0.00
当前EV/EBITDA
0.00
高估
0.00
低估
0.00

预期市销率

严重低估
5 年均值 P/S
0.00
当前P/S
0.00
高估
0.00
低估
0.00

Alphio AI 对 WORX 的价格情景

情景价格取自当年最后一个月度预测区间。概率为固定的模型权重(25 / 50 / 25),不构成保证。

乐

乐观

乐观 · 25%WORX

$0.50

情景价格

基

基准

基准 · 50%WORX

$0.50

情景价格

悲

悲观

悲观 · 25%WORX

$0.42

情景价格

事件时间线

2026-10-19 (ET)

10:30:00

SCWorx Enters New Agreement with Community Healthcare System

2026-10-08 (ET)

12:30:00

Scworx Corp Trading Halted Due to Volatility

12:30:00

Scworx Corp Trading Resumes

2026-10-05 (ET)

13:30:00

SCWorx Granted Continued Listing on Nasdaq

2026-08-06 (ET)

11:30:00

SCWorx Signs Two-Year Agreement with Major Massachusetts Healthcare Network

资讯

WORX 常见问题 —— 由 Alphio AI 解答

SCWorx Corp. is a provider of data content and services related to the repair, normalization and interoperability of information for healthcare providers, as well as big data analytics for the healthcare industry. The Company has developed and markets health care information technology solutions and associated services that enhance healthcare processes and information flow within hospitals and other healthcare facilities. Its software enables a healthcare provider to simplify and organize its data (data normalization), allows the data to be utilized across multiple internal software applications and provides the basis for sophisticated data analytics (big data). Its software modules include virtualized item master file repair, expansion and automation, electronic medical record management, charge description master management, contract management, request for proposal (RFP) automation, integration of acquired businesses, rebate management, and data integration and warehousing. It operates in the Industrials sector (SERVICES-MISCELLANEOUS AMUSEMENT & RECREATION industry).

Worx Corp is not a good buy right now due to significant declines in stock performance and negative financial indicators. The current price is $1.38, which is down 96.22% year-to-date, indicating severe underperformance. Additionally, the RSI is at an extremely low level of 5.451, suggesting that the stock is oversold, but this could also indicate a lack of buying interest. The forward P/E ratio is 0, reflecting no expected earnings growth, and the gross margin, while improving to 46.67% in Q2 2026, is overshadowed by a net margin of -17.13%. The main risk is the substantial 94.04% decline over the past 20 days, indicating a strong downward trend.

暂无帖子

注册或登录后参与讨论

本页仅供研究参考,不构成投资建议。模型可能出错。过往表现不代表未来结果。

开始交易